Skip to content
Stork.AIstork.ai
AI Tool

ProteinQure Review

ProteinQure is a clinical-stage biotech company that utilizes its AI-powered ProteinStudio™ platform for the de novo design of novel exotic peptides and tissue-specific drug delivery.

shipped Jul 9, 2026paid
Domain rating50Monthly visits100/mo
ProteinQure — product screenshot

Why it matters

1ProteinQure's lead candidate, PQ203, entered Phase I clinical trials in September 2025 for advanced metastatic solid tumors.
2The company secured $11 million in Series A funding in May 2025, contributing to a total funding of $16 million.
3ProteinStudio™ integrates multi-objective optimization algorithms and custom AI models on petascale supercomputers.
4The platform enables the design of peptides incorporating thousands of non-natural amino acids.

Specs

GitHub

View Repository →

API Available

Yes, public API

overview

What is ProteinQure?

ProteinQure is a clinical-stage biotechnology tool developed by ProteinQure that enables drug developers and researchers to design novel exotic peptides for therapeutic applications. Its ProteinStudio™ platform leverages AI, machine learning, and computational biophysics for de novo peptide design and tissue-specific drug delivery. ProteinQure specializes in creating peptide-drug conjugates (PDCs) with precise tissue- and cell-specific delivery capabilities, aiming to optimize therapeutic efficacy and minimize off-target effects. The ProteinStudio™ platform utilizes multi-objective optimization algorithms, custom-trained AI models, and advanced molecular simulations on petascale supercomputers to explore vast peptide libraries, including those incorporating thousands of non-natural amino acids. This approach facilitates the development of unique molecular scaffolds for addressing previously inaccessible biological targets across oncology, neurology, nephrology, and rare diseases.

features

Key Features of ProteinQure

ProteinQure's ProteinStudio™ platform offers a comprehensive suite of capabilities for the AI-driven design and optimization of therapeutic peptides, focusing on precision and targeted delivery.

  • AI-powered ProteinStudio™ platform for de novo peptide design.
  • Tissue-specific drug delivery capabilities for therapeutic payloads.
  • Leverages peptide-drug conjugates (PDCs) for precise therapeutic delivery.
  • Combines predictive power with deep structural insights into peptides and proteins.
  • Harnesses molecular simulations and custom AI models on petascale supercomputers.
  • Enables creation of unique molecular scaffolds using thousands of non-natural amino acids.
  • Integrates high-quality in-house assays for peptide validation.
  • Designs peptides with flexible building blocks and novel chemistries for diverse conjugations.

use cases

Who Should Use ProteinQure?

ProteinQure's platform is primarily utilized by pharmaceutical companies, biotech researchers, and drug developers focused on creating advanced peptide-based therapeutics with enhanced specificity and reduced systemic toxicity.

  • Oncology Researchers: For designing targeted cancer therapies, such as Peptide-Drug Conjugates (PDCs) that deliver cytotoxic agents to specific tumor cells (e.g., via Sortilin [SORT1] Delivery System for TNBC).
  • Drug Discovery Scientists: To develop novel exotic peptides for broad therapeutic applications, including addressing previously inaccessible biological targets.
  • Precision Medicine Developers: For engineering therapeutics with precision tissue- and cell-specific delivery, optimizing efficacy and minimizing off-target effects.
  • Neurology and Nephrology Programs: For designing peptides capable of crossing biological barriers like the blood-brain barrier or targeting specific renal tissues.

how to use

How to Use ProteinQure

Engagement with ProteinQure typically involves collaborative partnerships for drug discovery and development, leveraging their specialized AI platform and expertise in peptide engineering.

  • 1Initiate contact via the official ProteinQure website (www.proteinqure.com) to discuss potential collaborations.
  • 2Present specific therapeutic targets or unmet medical needs requiring novel peptide solutions.
  • 3Collaborate with ProteinQure's scientific team to define project scope and design parameters for peptide candidates.
  • 4Utilize the ProteinStudio™ platform's capabilities for computational design and optimization of exotic peptides.
  • 5Advance lead candidates through preclinical validation and subsequent clinical development, such as the ongoing Phase I trial for PQ203.

pricing

ProteinQure Pricing & Plans

ProteinQure operates on a paid, enterprise-level business model, offering its ProteinStudio™ platform and drug discovery services through collaborative partnerships. Specific pricing details are not publicly disclosed and are determined through direct engagement and negotiation based on project scope, intellectual property arrangements, and development milestones.

  • Custom Enterprise Solutions: Pricing determined per partnership agreement.

Pros

  • +Specialized focus on de novo design of 'exotic peptides' using non-natural amino acids.
  • +Advanced AI-powered ProteinStudio™ platform leveraging petascale supercomputers for complex simulations.
  • +Proven capability in developing peptide-drug conjugates (PDCs) for tissue-specific delivery.
  • +Lead candidate (PQ203) has progressed to Phase I clinical trials and received FDA Fast Track designation.
  • +Strong investor confidence demonstrated by significant Series A funding and government grants.
  • +Potential for optimized therapeutic efficacy and minimized off-target effects through precise targeting.

Cons

  • −As a clinical-stage biotech, the platform's full commercial availability and broad accessibility are limited.
  • −Pricing is not publicly disclosed, requiring direct engagement for cost assessment.
  • −Focus on peptides may limit applicability compared to platforms designing broader classes of biologics or small molecules.
  • −The drug development timeline is inherently long and high-risk, typical for clinical-stage companies.
  • −Requires specialized expertise to engage with and leverage the platform for drug discovery.

Similar Tools

ProteinQure vs Competitors

ProteinQure operates within the competitive landscape of AI-driven drug discovery, specifically focusing on peptide therapeutics. Its differentiation lies in the specialized de novo design of "exotic peptides" and an explicit emphasis on tissue-specific drug delivery using its ProteinStudio™ platform.

1
Insilico MedicineOn Stork

Utilizes a 'Generative Biologics' AI engine to design and optimize various biologics, including peptides, with a focus on rapid generation and optimization.

Similar to ProteinQure, Insilico Medicine uses generative AI for peptide design and has clinical-stage assets. However, Insilico's platform is broader, encompassing small molecules and other biologics, whereas ProteinQure specializes specifically in exotic peptides and tissue-specific delivery.

2
PeptiOrigin↗

Integrates advanced artificial intelligence with a comprehensive peptide database to accelerate hit discovery, structure-activity relationship (SAR) analysis, and de novo peptide design.

PeptiOrigin directly competes with ProteinQure in AI-driven de novo peptide design and optimization for therapeutic applications. Both companies focus on peptides, but ProteinQure emphasizes 'exotic peptides' and 'tissue-specific delivery' more explicitly.

3
Receptor.AI↗

Offers a multiplatform AI ecosystem with a dedicated 'Peptide Platform' for de novo binder design, including orally bioavailable peptides and targeting intracellular proteins.

Receptor.AI's peptide platform is a direct competitor, focusing on de novo peptide design and optimization, similar to ProteinQure. Receptor.AI also highlights orally bioavailable peptides, which could be a specific delivery advantage, similar to ProteinQure's tissue-specific delivery focus.

4
Aizen Therapeutics↗

Leverages a novel AI model (DaX™) for designing oral biologics, specifically focusing on non-canonical amino acid (ncAA) peptides and D-peptides.

Aizen Therapeutics is a strong direct competitor due to its explicit focus on AI-engineered 'oral biologics beyond nature' and the design of ncAA and D-peptides, which aligns well with ProteinQure's 'novel exotic peptides' using non-natural amino acids. Both aim for advanced therapeutic properties.

More on Stork

Related AI Tools

Other tools in this category, matched by shared tags

GPT WatermarkerSurroundersLifeOS AIWulver: Daily Workout StreaksGenifyPlanPulse
Visit ProteinQure↗
Connect
𝕏
X / Twitterx.com/proteinqure
⌘
GitHubgithub.com/proteinqure
in
LinkedInwww.linkedin.com/company/proteinqure/